Successful cases of percutaneous left ventricular assist device "Impella" to fulminant myocarditis

• Published in: Journal of cardiothoracic surgery Vol. 17; no. 1; p. 72
• Main Authors: Hori, Takayuki, Iida, Mitsuru, Uchiyama, Masateru, Shimokawa, Tomoki
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 12.04.2022; BioMed Central; BMC
• Subjects: Blood tests; Cardiac arrhythmia; Cardiac function; Carditis; Case Report; Complications; Congestive heart failure; Ejection fraction; Extracorporeal membrane oxygenation; Fulminant myocarditis; Heart; Heart failure; Heart Failure - complications; Heart Failure - surgery; Heart-Assist Devices - adverse effects; Hemodynamics; Hospitals; Humans; Impella; Inflammation; Lactates; Lactic acid; Myocarditis; Myocarditis - surgery; Ostomy; Patients; Percutaneous left ventricular assist device; Shock, Cardiogenic - etiology; Transplants & implants; Treatment Outcome; Veins & arteries; Ventricle; Vital signs; Japan; Impella; Fulminant myocarditis; Percutaneous left ventricular assist device
• ISSN: 1749-8090; 1749-8090
• DOI: 10.1186/s13019-022-01821-x

Fulminant myocarditis (FM) is a form of severe inflammatory carditis with rapidly developing acute heart failure. We report three cases of successful intensive treatment by Impella of FM without any complications. In all cases, impairment of microcirculation as measured by blood lactate level and the hemodynamic value as indicated by cardiac index were improved within 24-48 h and 7 days after Impella implantation, respectively. Interestingly, our data also suggested that treatment by Impella CP or 5.0 may lead to faster recovery of microcirculation and cardiac function than treatment by Impella 2.5. Our findings demonstrate that the appropriate selection of Impella devices guided by body surface area measurements may help to improve clinical outcomes of severe heart failure including FM.